SWOG S0722: Phase II study of mTOR inhibitor everolimus (RAD001) in advanced Malignant Pleural Mesothelioma (MPM)

Journal of Thoracic Oncology

Volumn 10, Issue 2, 2015, Pages 387-391

  Ou, Sai Hong Ignatius ^a   Moon, James ^b   Garland, Linda L ^c   Mack, Philip C ^d   Testa, Joseph R ^e   Tsao, Anne S ^f   Wozniak, Antoniette J ^g   Gandara, David R ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b USA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Everolimus; Malignant pleural mesothelioma; Modified RECIST; mTOR inhibitor

Indexed keywords

CHOLESTEROL; CREATININE; EVEROLIMUS; HEMOGLOBIN; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; DEHYDRATION; DIARRHEA; DRUG ERUPTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INTERNATIONAL NORMALIZED RATIO; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LUNG INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; NAUSEA; ORAL MUCOSITIS; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; TREATMENT DURATION; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; PATHOLOGY; PLEURAL NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; EVEROLIMUS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84922246665     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000360     Document Type: Article

References (15)

1. Suzuki Y, Murakami H, Kawaguchi K, et al. Activation of the PI3K-AKT pathway in human malignant mesothelioma cells. Mol Med Rep 2009;2: 181-188
2. Altomare DA, You H, Xiao GH, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 2005;24: 6080-6089
3. Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol 2007;25:2406-2413
4. Cedrés S, Montero MA, Martinez P, et al. Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer 2012;77:192-198
5. Barbone D, Yang TM, Morgan JR, Gaudino G, Broaddus VC. Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids. J Biol Chem 2008;283:13021-13030
6. Ranzato E, Grosso S, Patrone M, Betta PG, Viarengo A, Biffo S. Spreading of mesothelioma cells is rapamycin-sensitive and requires continuing translation. J Cell Biochem 2009;108:867-876
7. Hartman ML, Esposito JM, Yeap BY, Sugarbaker DJ. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma. J Thorac Cardiovasc Surg 2010;139:1233-1240
8. Hoda MA, Mohamed A, Ghanim B, et al. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy. J Thorac Oncol 2011;6:852-863
9. Lebwohl D, Anak O, Sahmoud T, et al. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases. Ann N Y Acad Sci 2013;1291:14-32
10. Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol 2011;6:598-601
11. Francart J, Vaes E, Henrard S, et al. A prognostic index for progressionfree survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials. Eur J Cancer 2009;45:2304-2311
12. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41
13. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E. Functional inactivation of NF2/merlin in human mesothelioma. Lung Cancer 2009;64:140-147
14. López-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG. Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 2009;29:4235-4249
15. Bitanihirwe BK, Meerang M, Friess M, et al. PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy. J Thorac Oncol 2014;9:239-247